Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of cabergoline versus bromocriptine in women with hyperprolactinemia
CTR20253253Phase 3Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabergoline, bromocriptine in hyperprolactinemia, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
cabergolinebromocriptine
03
Conditions
hyperprolactinemia
Beyond the preview
Go deeper on CTR20253253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253253.